← All Serina Therapeutics, INC filings

Serina Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

AMEX
SER
Serina Therapeutics, INC
10-K/A: Serina Therapeutics Amends 2025 10-K for Auditor Consent
Serina Therapeutics, Inc. filed an Amendment No. 1 to its 2025 Annual Report on Form 10-K to correct an inadvertently incorrect Auditor Consent and include new certifications from its principal executive and financial officers.
AMEX
SER
Serina Therapeutics, INC
10-K: Serina Therapeutics Reports Deepening Losses, Secures New Funding Amidst Parkinson's Drug Advancement
Serina Therapeutics, a clinical-stage biotechnology company, reported a significant increase in net losses for 2025, alongside ongoing concerns about its ability to continue as a going concern, despite advancing its lead Parkinson's disease candidate, SER-252, into Phase 1b clinical trials and securing new capital.
AMEX
SER
Serina Therapeutics, INC
10-K: Serina Therapeutics Navigates Reverse Merger, Charts Course for Parkinson's Therapies
Serina Therapeutics completes a reverse merger, transitioning its focus to developing novel Parkinson's disease treatments using its POZ platform technology.
AMEX
SER
Serina Therapeutics, INC
10-K: AgeX Therapeutics Announces Post-Merger Warrant Issuance and Merger Details
AgeX Therapeutics has detailed the issuance of post-merger warrants to its shareholders and provided updates on its planned merger with Serina Therapeutics.